NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Should l Buy ?
Source: PRnewswire
Merger Announcement: NLS Pharmaceutics and Kadimastem have signed a Memorandum of Understanding to collaborate under the new company, NewCelX, following their anticipated merger.
Focus on Advanced Therapies: The partnership aims to enhance the development of innovative therapies for severe diseases, leveraging Kadimastem's cell therapy solutions and TargetGene's precision gene-editing technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
